Vir Biotechnology Analyst Ratings

BenzingaApr 17 13:50 ET · Ratings

Goldman Sachs Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $21

Moomoo NewsApr 16 11:31 ET · Ratings

Prelude to increased tariffs? The Trump administration has initiated a Section 232 investigation into pharmaceuticals and Semiconductors.

① The USA government disclosed on Monday that it has launched an investigation into the impact of imported Pharmaceuticals and Semiconductors on National Security; ② This is widely seen as a prelude to imposing tariffs on prescription drugs and Semiconductors, and it could further escalate the trade war initiated by the USA.

cls.cnApr 14 20:14 ET

Vir Biotechnology CEO & Director Marianne De Backer Sells 33% Of Holding

Simply Wall StApr 10 06:20 ET

Vir Biotechnology Insider Sold Shares Worth $474,239, According to a Recent SEC Filing

MT NewswiresApr 4 16:28 ET

Vir Biotechnology, Inc. (NASDAQ:VIR) Is Favoured by Institutional Owners Who Hold 53% of the Company

Yahoo FinanceMar 28 08:24 ET